Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
This study correlates in vivo findings in a patient with an extensively drug-resistant (XDR) <i>P. aeruginosa</i> infection who developed resistance to ceftazidime-avibactam (CAZ-AVI) with in vitro results of a 7-day hollow-fiber infection model (HFIM) testing the same bacterial strain. The patient...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2022-10-01
|
| Ráidu: | Antibiotics |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2079-6382/11/11/1456 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
